Comparing an AI test to a 21-gene assay for premenopausal node-positive HR+/HER2- breast cancer
Elayoubi, J.; Tang, C.; Ruddy, K. J.; Choucair, K.; Kalinsky, K.; Pogoda, K.; Esteva, F. J.; Abdelsattar, J. M.; Borges, V. F.; Zeng, K.; Cappadona, J.; Machura, B.; Biswas, D.; Geras, K. J.; Witowski, J.
Show abstract
Recurrence scores based on a 21-gene assay are clinically useful for predicting prognosis and chemotherapy benefit in postmenopausal node-positive breast cancer patients, but its performance in premenopausal patients is inconsistent. Here, we evaluated Ataraxis Breast RISK (ATX), an AI test that predicts recurrence risk, and compared it with the genomic assay. ATX identified high risk patients misclassified as low risk by the genomic assay and therefore may refine selection of patients for adjuvant chemotherapy.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- RNA Sequencing-Based Single Sample Predictors of Molecular Subtype and Risk of Recurrence for Clinical Assessment of Early-Stage Breast Cancer 97%
- The clinical and molecular significance associated with STING signaling in estrogen receptor-positive early breast cancer 96%
- A 20-feature radiomic signature of triple-negative breast cancer identifies patients at high risk of death 95%
Similar papers in this journal
- Clinicogenomic characterization of inflammatory breast cancer 95%
- Clinical Validation of Digital PCR-based ctDNA detection for risk stratification in residual triple negative breast cancer: TRICIA trial results 94%
- Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors 93%
Similar papers in this journal
- Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy 95%
- Development and prognostic validation of a three-level NHG-like deep learning-based model for histological grading of breast cancer 95%
- Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences 94%
Similar papers in this journal
- Development and validation of a gene expression score to account for tumour purity and improve prognostication in breast cancer 94%
- Germline genomic landscapes of breast cancer patients significantly predict clinical outcomes 93%
- Deep learning inference of cell type-specific gene expression from breast tumor histopathology 93%
Similar papers in this journal
- Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping, Prognostic Classification, and Predicts Response to Antibody Drug Conjugates 96%
- Deep Learning Allows Assessment of Risk of Metastatic Relapse from Invasive Breast Cancer Histological Slides 94%
- Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.